You are here:

bortezomib (Velcade)

Advice

following a full submission

bortezomib (Velcade®) is accepted for use within NHS Scotland.

Indication under review: in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone significantly improved progression-free survival compared to a regimen containing rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in adults with previously untreated mantle cell lymphoma who were unsuitable for haematopoietic stem cell transplantation.

Drug Details

Drug Name: bortezomib (Velcade)
SMC Drug ID: 1075/15
Manufacturer: Janssen-Cilag Ltd
Indication: In combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 7 September 2015

Back